News
Zacks Investment Research on MSN21h
Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU
Madrigal Pharmaceuticals MDGL announced that the European Commission (EC) has granted a conditional marketing authorization ...
The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.
Pharmaceutical Technology on MSN1d
Madrigal wins European MASH approval as Novo rivalry looms
"Madrigal wins European MASH approval as Novo rivalry looms" was originally created and published by Pharmaceutical ...
Although there are other treatments in development, Wegovy could carve out a decent market for itself in MASH, especially ...
Conshohocken, Pennsylvania Thursday, August 21, 2025, 14:00 Hrs [IST] ...
Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 ...
With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...
Everyday Health on MSN1d
People With Weight-Related Chronic Liver Disease Have a New Treatment Option
The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...
The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...
Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s ...
About Rezdiffra Rezdiffra is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. It is the first approved medication for the treatment of MASH in ...
Rezdiffra is the first and only medication approved for people living with MASH in the European Union <li /> Conditional marketing au ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback